William Shingler

939 total citations
26 papers, 697 citations indexed

About

William Shingler is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, William Shingler has authored 26 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 14 papers in Oncology and 10 papers in Genetics. Recurrent topics in William Shingler's work include Immunotherapy and Immune Responses (16 papers), Virus-based gene therapy research (10 papers) and CAR-T cell therapy research (9 papers). William Shingler is often cited by papers focused on Immunotherapy and Immune Responses (16 papers), Virus-based gene therapy research (10 papers) and CAR-T cell therapy research (9 papers). William Shingler collaborates with scholars based in United Kingdom, United States and Cyprus. William Shingler's co-authors include Richard Harrop, Stuart Naylor, Jackie de Belin, Robert J. Amato, P. Chikoti, Robert E. Hawkins, Susan M. Kingsman, Howard L. Kaufman, Noel Drury and Miles W. Carroll and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

William Shingler

23 papers receiving 685 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William Shingler United Kingdom	13	435	380	191	149	116	26	697
Gail DeRaffele United States	12	624 1.4×	785 2.1×	336 1.8×	392 2.6×	98 0.8×	19	1.1k
Irina Redchenko United Kingdom	13	606 1.4×	599 1.6×	188 1.0×	158 1.1×	31 0.3×	20	919
Franco Marincola United States	14	1.1k 2.4×	627 1.6×	385 2.0×	96 0.6×	50 0.4×	20	1.3k
Derek Ng Tang United States	10	757 1.7×	811 2.1×	281 1.5×	46 0.3×	97 0.8×	18	1.2k
Michal Šmahel Czechia	15	462 1.1×	171 0.5×	263 1.4×	103 0.7×	25 0.2×	59	783
Tobias Flecken Germany	10	344 0.8×	291 0.8×	136 0.7×	68 0.5×	40 0.3×	12	664
Jacob Ricca United States	8	392 0.9×	583 1.5×	297 1.6×	340 2.3×	84 0.7×	12	933
Xiaochuan Shan United States	12	372 0.9×	235 0.6×	356 1.9×	143 1.0×	17 0.1×	20	779
Maximillian Rosario United States	11	945 2.2×	541 1.4×	150 0.8×	61 0.4×	25 0.2×	19	1.1k
Annette Arnold Germany	12	827 1.9×	522 1.4×	262 1.4×	198 1.3×	48 0.4×	17	1.2k

Countries citing papers authored by William Shingler

Since Specialization

Citations

This map shows the geographic impact of William Shingler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Shingler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Shingler more than expected).

Fields of papers citing papers by William Shingler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Shingler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Shingler. The network helps show where William Shingler may publish in the future.

Co-authorship network of co-authors of William Shingler

This figure shows the co-authorship network connecting the top 25 collaborators of William Shingler. A scholar is included among the top collaborators of William Shingler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Shingler. William Shingler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barnes, Linda, et al.. (2024). Risk-Based Qualification of Cellular Starting Material Collection Sites: Tools to Determine Scope of Manufacturer Audits and Reduce Duplicative Efforts. Transplantation and Cellular Therapy. 30(12). 1171–1177.

Middleton, Mark R., Neil Steven, Jeffrey R. Infante, et al.. (2016). Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.. Journal of Clinical Oncology. 34(15_suppl). 3016–3016. 37 indexed citations

Middleton, Mark R., Pippa Corrie, Mario Sznol, et al.. (2015). A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma. Cancer Research. 75. 3 indexed citations

Middleton, Mark R., Pippa Corrie, Mario Sznol, et al.. (2015). Abstract CT106: A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma. Cancer Research. 75(15_Supplement). CT106–CT106. 5 indexed citations

Middleton, Mark R., JEFF EVANS, Neil Steven, et al.. (2014). A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma. Cancer Research. 74. 1 indexed citations

Middleton, Mark R., JEFF EVANS, Neil Steven, et al.. (2014). Abstract CT329: A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma. Cancer Research. 74(19_Supplement). CT329–CT329. 1 indexed citations

Middleton, Mark R., Jason V. Evans, Neil Steven, et al.. (2013). IMCgp100: a novel bispecific biologic for the treatment of malignant melanoma.. Cancer Research. 73. 2 indexed citations

Harrop, Richard, Peter Treasure, Jackie de Belin, et al.. (2012). Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax). Cancer Immunology Immunotherapy. 61(12). 2283–2294. 19 indexed citations

Harrop, Richard, William Shingler, Peter Treasure, et al.. (2011). MVA–5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunology Immunotherapy. 60(6). 829–837. 22 indexed citations

10.

Harrop, Richard, William Shingler, Michelle Kelleher, Jackie de Belin, & Peter Treasure. (2010). Cross-trial Analysis of Immunologic and Clinical Data Resulting From Phase I and II Trials of MVA-5T4 (TroVax) in Colorectal, Renal, and Prostate Cancer Patients. Journal of Immunotherapy. 33(9). 999–1005. 28 indexed citations

11.

Kaufman, Howard L., Bret Taback, William H. Sherman, et al.. (2009). Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. Journal of Translational Medicine. 7(1). 2–2. 55 indexed citations

12.

Hawkins, Robert E., Fiona Thistlethwaite, Noel Drury, et al.. (2009). Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α. Journal of Immunotherapy. 32(4). 424–429. 36 indexed citations

13.

Amato, Robert J., William Shingler, Jackie de Belin, et al.. (2009). Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α). Journal of Immunotherapy. 32(7). 765–772. 55 indexed citations

14.

Shingler, William, P. Chikoti, Susan M. Kingsman, & Richard Harrop. (2008). Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. International Immunology. 20(8). 1057–1066. 22 indexed citations

15.

Harrop, Richard, Fiona Thistlethwaite, Noel Drury, et al.. (2008). Vaccination of renal cell cancer patients with TroVax (modified vaccinia Ankara delivering the tumor antigen 5T4) plus IFNα: A phase II trial. Journal of Clinical Oncology. 26(15_suppl). 3053–3053. 4 indexed citations

16.

Kaufman, Howard L., Seunghee Kim‐Schulze, Dorota Moroziewicz, et al.. (2008). Correlation of effector and regulatory T cell responses with clinical outcome in metastatic renal cell carcinoma patients treated with MVA-5T4 vaccine and high-dose interleukin-2. Journal of Clinical Oncology. 26(15_suppl). 3004–3004. 1 indexed citations

17.

Hernandez-McClain, Joan, J. P. Willis, Richard Harrop, et al.. (2007). Activity of MVA 5T4 alone or in combination with either interleukin-2 (IL-2) or interferon-α (IFN) in patients (Pts) with metastatic renal cell cancer (MRCC). Journal of Clinical Oncology. 25(18_suppl). 3069–3069. 6 indexed citations

18.

Harrop, Richard, Noel Drury, William Shingler, et al.. (2007). Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunology Immunotherapy. 57(7). 977–986. 63 indexed citations

19.

Harrop, Richard, Noel Drury, William Shingler, et al.. (2007). Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses. Clinical Cancer Research. 13(15). 4487–4494. 73 indexed citations

20.

Devitt, Andrew, Sarah Pierce, Ceri Oldreive, William Shingler, & Christopher D. Gregory. (2003). CD14-dependent clearance of apoptotic cells by human macrophages: the role of phosphatidylserine. Cell Death and Differentiation. 10(3). 371–382. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact